All Updates

All Updates

icon
Filter
Partnerships
Exscientia partners with Charité to develop precision medicine platform
AI Drug Discovery
Mar 7, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Mar 7, 2023

Exscientia partners with Charité to develop precision medicine platform

Partnerships

  • UK-based AI biotechnology company Exscientia partnered with one of Europe’s largest university hospitals, Charité, to use Exscientia’s AI-based precision medicine platform in the treatment of hematological cancers.  

  • Charité will assess Exscientia’s precision medicine platform capabilities in identifying effective treatments for hematological cancer patients. This involves testing various drugs, including those that have not yet been approved for this condition, on patient samples to determine their response.  

  • The partnership will build on the findings of the EXALT-1 study. This study showed that Exscientia’s drug testing platform, which provides personalized treatment recommendations, resulted in significantly better outcomes for patients with advanced hematologic cancer compared to the treatment chosen by physicians. Charité will also create a biobank of cryopreserved blood, bone marrow, and lymph node tissues (which includes live human tissue samples) to assist in the advancement of technology and preclinical research projects at both companies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.